Francesco Saraceni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francesco Saraceni has a total of 301 co-authors. Here are the top co-authors by number of shared publications:
Mohamad Mohty
EBMT Paris Study Office Saint Antoine Hospital Paris France
5 shared publicationsArnon Nagler
Department of Bone Marrow Transplantation Chaim Sheba Medical Center Tel‐Hashomer Israel
4 shared publicationsAttilio Olivieri
13Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
4 shared publications- Attilio Olivieri
11Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
4 shared publications - Bipin N. Savani
Vanderbilt University Medical Center, Nashville, TN, USA
4 shared publications Irene Federici
Hematology Department, University Hospital, Ancona, Italy
4 shared publications
Latest Publications
- 5 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1547-1550
Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo)
- 5 August 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (11) , 1547-1550
Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo)
- 2 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1-9
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients
Two hundred and fifty-eight patients with newly diagnosed cGVHD have been enrolled in a multicenter study (NCT02991846). Primary endpoint was failure free survival (FFS); secondary endpoints were ORR at 6 and 12 months after best available therapy (BAT) and OS. Response evaluation was supported by a software (Crosy) collecting cGvHD master data. Software-assisted (SA) response and clinician-based (CB) evaluation, according to NIH criteria, have been performed in parallel at 6 and 12 months. Among 258 patients, 200 needed systemic therapy (ST); 167 were evaluable for response; ORR according to SA was 62% (CR:19%; PR: 43%), and 65% (CR: 23%; PR: 42%) according to the CB evaluation; overall agreement was 66%. In multivariate analysis, only 6-month SA response significantly predicted OS, being more effective in capturing Mixed Responses, compared to CB evaluation. After 12 months 23% of patients were able to stop ST: significantly more patients who maintained ST1 stopped ST (39%) than those who requested a ST1 change (9,5%); (p < 0.001). The 2-year FFS of patients receiving ST was 67%; 2-year OS was 85%: 32 patients (18%) died (30 due to cGVHD progression or causes coexisting with cGvHD). SA evaluation of response in cGVHD is reliable and predicts FFS.
- 2 July 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1-9
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients
Two hundred and fifty-eight patients with newly diagnosed cGVHD have been enrolled in a multicenter study (NCT02991846). Primary endpoint was failure free survival (FFS); secondary endpoints were ORR at 6 and 12 months after best available therapy (BAT) and OS. Response evaluation was supported by a software (Crosy) collecting cGvHD master data. Software-assisted (SA) response and clinician-based (CB) evaluation, according to NIH criteria, have been performed in parallel at 6 and 12 months. Among 258 patients, 200 needed systemic therapy (ST); 167 were evaluable for response; ORR according to SA was 62% (CR:19%; PR: 43%), and 65% (CR: 23%; PR: 42%) according to the CB evaluation; overall agreement was 66%. In multivariate analysis, only 6-month SA response significantly predicted OS, being more effective in capturing Mixed Responses, compared to CB evaluation. After 12 months 23% of patients were able to stop ST: significantly more patients who maintained ST1 stopped ST (39%) than those who requested a ST1 change (9,5%); (p < 0.001). The 2-year FFS of patients receiving ST was 67%; 2-year OS was 85%: 32 patients (18%) died (30 due to cGVHD progression or causes coexisting with cGvHD). SA evaluation of response in cGVHD is reliable and predicts FFS.
- Open Access
- 24 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1176-1181
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first complete remission
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and efficacy of FT14 conditioning regimen in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in first complete remission.(EudraCT Number:2021-006515-28; Clinical trial number NCT07232953). The study was designed to provide a non-inferior alternative to standard busulfan-containing regimens, which would enable effective transplantation while minimizing toxicity. The primary objective was 1-year Leukemia-free survival (LFS). In total, 82 patients were enrolled in the study with a median follow up of 19.7 months; donor used were matched sibling in 22, matched unrelated 52 and mismatched unrelated in 8 cases, respectively. LFS at 180-day and 365-day were 87.8% and 81.7%, respectively. Cumulative incidence of relapse at 1 year after allo-HSCT was 14.9% with mean time to relapse of 5.6 months. Also, FT14 regimen provided an excellent safety with nearly absent NRM, no cases of septic death, and no cases of primary graft failure. Our study supports the use of FT14 as effective myeloablative conditioning regimen for AML patients aged 40–65 y in first complete remission, especially in patients for whom busulfan based conditioning regimens poses excessive toxic risks.
- 24 June 2026
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 61 (9) , 1176-1181
Open AccessA phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40–65 in first complete remission
Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and efficacy of FT14 conditioning regimen in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in first complete remission.(EudraCT Number:2021-006515-28; Clinical trial number NCT07232953). The study was designed to provide a non-inferior alternative to standard busulfan-containing regimens, which would enable effective transplantation while minimizing toxicity. The primary objective was 1-year Leukemia-free survival (LFS). In total, 82 patients were enrolled in the study with a median follow up of 19.7 months; donor used were matched sibling in 22, matched unrelated 52 and mismatched unrelated in 8 cases, respectively. LFS at 180-day and 365-day were 87.8% and 81.7%, respectively. Cumulative incidence of relapse at 1 year after allo-HSCT was 14.9% with mean time to relapse of 5.6 months. Also, FT14 regimen provided an excellent safety with nearly absent NRM, no cases of septic death, and no cases of primary graft failure. Our study supports the use of FT14 as effective myeloablative conditioning regimen for AML patients aged 40–65 y in first complete remission, especially in patients for whom busulfan based conditioning regimens poses excessive toxic risks.
- 26 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1406-1409
Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy
- 26 July 2025
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 60 (10) , 1406-1409
Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy
- 24 April 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 63 (3) , 103935
Focus on: Prognostic scores to predict stem cell mobilization
- 24 April 2024
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 63 (3) , 103935
Focus on: Prognostic scores to predict stem cell mobilization
- Top Cited PapersOpen Access
- 15 March 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (6) , 1444-1448
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
- 15 March 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (6) , 1444-1448
Top Cited PapersOpen AccessAllogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (Suppl) , e1610525
PB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (Suppl) , e1610525
Open AccessPB1840: OUTCOME OF ADULT ACUTE MYELOID LEUKEMIA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER TREATMENT WITH VENETOCLAX/HYPOMETHYLATING AGENTS
- Open Access
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1105523
Editorial: Reviews in hematologic malignancies
Editorial: Reviews in hematologic malignancies
- 22 December 2022
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 1105523
Open AccessEditorial: Reviews in hematologic malignancies
Editorial: Reviews in hematologic malignancies
- Open Access
Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
FLT3 ITD and TKD mutations occur in 20% and 10% of Acute Myeloid Leukemia (AML), respectively, and they represent the target of the first approved anti-leukemic therapies in the 2000s. Type I and type II FLT3 inhibitors (FLT3i) are active against FLT3 TKD/ITD and FLT3 ITD mutations alone respectively, but they still fail remissions in 30–40% of patients due to primary and secondary mechanisms of resistance, with variable relapse rate of 30–50%, influenced by NPM status and FLT3 allelic ratio. Mechanisms of resistance to FLT3i have recently been analyzed through NGS and single cell assays that have identified and elucidated the polyclonal nature of relapse in clinical and preclinical studies, summarized here. Knowledge of tumor escape pathways has helped in the identification of new targeted drugs to overcome resistance. Immunotherapy and combination or sequential use of BCL2 inhibitors and experimental drugs including aurora kinases, menin and JAK2 inhibitors will be the goal of present and future clinical trials, especially in patients with FLT3-mutated (FLT3mut) AML who are not eligible for allogeneic transplantation.
Open AccessOvercoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
FLT3 ITD and TKD mutations occur in 20% and 10% of Acute Myeloid Leukemia (AML), respectively, and they represent the target of the first approved anti-leukemic therapies in the 2000s. Type I and type II FLT3 inhibitors (FLT3i) are active against FLT3 TKD/ITD and FLT3 ITD mutations alone respectively, but they still fail remissions in 30–40% of patients due to primary and secondary mechanisms of resistance, with variable relapse rate of 30–50%, influenced by NPM status and FLT3 allelic ratio. Mechanisms of resistance to FLT3i have recently been analyzed through NGS and single cell assays that have identified and elucidated the polyclonal nature of relapse in clinical and preclinical studies, summarized here. Knowledge of tumor escape pathways has helped in the identification of new targeted drugs to overcome resistance. Immunotherapy and combination or sequential use of BCL2 inhibitors and experimental drugs including aurora kinases, menin and JAK2 inhibitors will be the goal of present and future clinical trials, especially in patients with FLT3-mutated (FLT3mut) AML who are not eligible for allogeneic transplantation.
- Open Access
Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical trials conducted in the first ten years of the twenty-first century established as standard therapy for these patients a therapeutic approach including induction, single or double ASCT, consolidation, and maintenance therapy. More recently, incorporating second-generation proteasome inhibitors carfilzomib and monoclonal antibody daratumumab into each phase of treatment significantly improved the efficacy of ASCT in terms of measurable residual disease (MRD) negativity, Progression Free Survival (PFS), and Overall Survival (OS). The availability of techniques such as multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for MRD assessment allowed the design of MRD-based response-adjusted trials that will define, in particular, the role of consolidation and maintenance therapies. In this review, we will provide an overview of the most recent evidence and the future prospects of ASCT in MM patients.
Open AccessAutologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
The introduction of high-dose therapy in the 1990s as well as the development of drugs such as thalidomide, lenalidomide, and bortezomib in the 2000s led to an impressive improvement in outcome of patients with multiple myeloma (MM) eligible for autologous stem cell transplantation (ASCT). Clinical trials conducted in the first ten years of the twenty-first century established as standard therapy for these patients a therapeutic approach including induction, single or double ASCT, consolidation, and maintenance therapy. More recently, incorporating second-generation proteasome inhibitors carfilzomib and monoclonal antibody daratumumab into each phase of treatment significantly improved the efficacy of ASCT in terms of measurable residual disease (MRD) negativity, Progression Free Survival (PFS), and Overall Survival (OS). The availability of techniques such as multiparameter flow cytometry (MFC) and next-generation sequencing (NGS) for MRD assessment allowed the design of MRD-based response-adjusted trials that will define, in particular, the role of consolidation and maintenance therapies. In this review, we will provide an overview of the most recent evidence and the future prospects of ASCT in MM patients.